Cargando…
Genetic polymorphisms of histone methyltransferase SETD2 predicts prognosis and chemotherapy response in Chinese acute myeloid leukemia patients
BACKGROUND: SETD2, the single mediator of trimethylation of histone 3 at position lysine 36, has been reported associated with initiation progression and chemotherapy resistance in acute myeloid leukemia (AML). Whether polymorphisms of SETD2 affect prognosis and chemotherapy response of AML remains...
Autores principales: | Wang, Suwei, Yuan, Xiaoqing, Liu, Yazhen, Zhu, Kewei, Chen, Peng, Yan, Han, Zhang, Daoyu, Li, Xi, Zeng, Hui, Zhao, Xielan, Chen, Xiaoping, Zhou, Gan, Cao, Shan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437967/ https://www.ncbi.nlm.nih.gov/pubmed/30922329 http://dx.doi.org/10.1186/s12967-019-1848-9 |
Ejemplares similares
-
Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells
por: Sheng, Yaru, et al.
Publicado: (2019) -
Inhibition of histone methyltransferase SETD8 represses DNA virus replication
por: Chen, Lin, et al.
Publicado: (2022) -
The histone methyltransferase SETD2 negatively regulates cell size
por: Molenaar, Thom M., et al.
Publicado: (2022) -
Discovery of a Non-Nucleoside SETD2 Methyltransferase Inhibitor against Acute Myeloid Leukemia
por: Bajusz, Dávid, et al.
Publicado: (2021) -
Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers
por: Chen, Rui, et al.
Publicado: (2020)